Evolution of androgen receptor targeted therapy for advanced prostate cancer.
about
Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDXThe endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis.PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/β-catenin signaling pathway.Sortilin regulates progranulin action in castration-resistant prostate cancer cellsRecurrent SKIL-activating rearrangements in ETS-negative prostate cancer.Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models.Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening.Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer.Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancerHollow boron nitride nanospheres as boron reservoir for prostate cancer treatment.Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Molecular insights into the development of T cell-based immunotherapy for prostate cancer.Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers.FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.Targeting the androgen receptor in breast cancer.Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.Regulation of prostate cancer progression by the tumor microenvironment.Cellular determinants and microenvironmental regulation of prostate cancer metastasis.In Vitro and In Vivo Efficacy Studies of Lavender angustifolia Essential Oil and Its Active Constituents on the Proliferation of Human Prostate Cancer.Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.Curcumin inhibits growth of prostate carcinoma via miR-208-mediated CDKN1A activation.Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancerVinculin and filamin-C are two potential prognostic biomarkers and therapeutic targets for prostate cancer cell migration.Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein.Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression.Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
P2860
Q26746524-DBE5FC34-C7A4-4744-8718-16D55EFF204CQ27348356-E49B8874-529F-4C3B-BA7C-8AF154F305C0Q30353562-FEA01DBE-EB1F-4A5D-A408-A154FBCA16EFQ33827484-CF2FD660-EA2C-46F9-88F4-16A348EF4F8DQ34745270-F1A2325F-FC98-4475-9104-1CEBBDBCEB1CQ35742514-3F421B4D-0BAB-427E-90F3-93B9B0C1E261Q36020949-924DB7F7-C46C-4773-A37D-492BE0BE4FEBQ36113762-BBB75B04-4A40-4351-8731-001029948F42Q36147506-D9573A6D-577D-4051-A32B-1F697FFFAAEEQ36323141-47905A6F-BAAA-41D8-BE0F-317DCC632C8AQ36738996-EC94E6A1-DB6B-445B-B95B-775556E514A9Q37065079-7664BF5C-618B-4572-9061-1DA4CB31F0FAQ37541830-E9C87B7C-AE24-424A-80E8-AEA917EC3A47Q37582113-CD52EBFC-B7C1-44DC-BA51-35AA91E9195AQ37682137-9ED16E65-6735-494B-9680-161BFBFF57B0Q37709535-CF5C47B5-BFC5-4E4D-BD6F-2409E78A5E56Q38254639-D90A4749-288A-4D34-9EAD-4664D6EA6352Q38261250-253794E6-6BA2-4BB6-B42E-87C9E3E24070Q38286227-7A971382-5DD4-482D-99AF-9972F3F76D13Q38298274-21D9527F-60F9-4195-B111-3EE8EAB3F90CQ38349376-8A2AD06C-ADA7-4A68-AB33-991D315774CDQ38643148-5B6B7A03-A490-46AC-8C26-7AEB17BB3248Q38717262-5559EBBC-903C-4769-AB7D-DA13EA5E6E71Q38730590-666160F5-DCE6-4971-A0CF-F3FC43E426C6Q38772862-342B90BE-3B1E-49EB-928A-94FBE0C86EDDQ38818338-CE16DF87-8082-4A09-B586-555098739A7CQ38846889-30093BFE-39B9-4A97-A898-DD7450239179Q38868809-998D6A70-6205-408F-A308-8983B29F796BQ38908290-72C7A14C-08F0-4366-AC3B-5334573D42DAQ41495773-3A78B993-D87C-4A59-A362-6A616AAE220AQ42188589-AE7CCDC3-FE0F-421C-9A3A-487797E5847BQ47152110-9FE73D66-BD45-4954-A428-BE379B48C2BDQ47433115-E782313C-7E19-4817-B86B-5D2D5E6E467EQ48022094-ECD0A41B-8635-4961-A8E4-D0085D8E0DADQ49578242-FCDF296B-753A-4A21-8586-615ACA717AD6Q50852820-382D9097-D31A-485F-8E19-BDE82208344CQ52771926-C613810E-215F-4F03-9A39-0E87CF55430EQ55082840-FC58C87C-A043-4E6E-B3FD-84CDADFE0CD4Q57804743-7394AFB0-8140-4642-83EC-52740D844D3C
P2860
Evolution of androgen receptor targeted therapy for advanced prostate cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Evolution of androgen receptor targeted therapy for advanced prostate cancer.
@en
type
label
Evolution of androgen receptor targeted therapy for advanced prostate cancer.
@en
prefLabel
Evolution of androgen receptor targeted therapy for advanced prostate cancer.
@en
P2093
P2860
P1476
Evolution of androgen receptor targeted therapy for advanced prostate cancer.
@en
P2093
Johann de Bono
Roberta Ferraldeschi
Yien Ning Sophia Wong
P2860
P2888
P304
P356
10.1038/NRCLINONC.2014.72
P407
P577
2014-05-20T00:00:00Z
P6179
1017890411